Medical artificial intelligence is rapidly evolving beyond its traditional role as an image-reading assistant, expanding into preventive healthcare and long-term disease management. Industry experts say recent advances in multi-disease analysis technology could significantly improve diagnostic efficiency and reshape future healthcare systems.
A growing area of focus in the medical AI sector is “multi-disease analysis,” which enables AI systems to detect multiple disease risks from a single CT scan. Traditionally, organs such as the heart, lungs, and blood vessels were examined separately through different diagnostic workflows. AI technologies are now moving toward integrated analysis capable of identifying various abnormalities simultaneously within one imaging dataset.
Cardiac CT, or coronary computed tomography angiography (CCTA), is one of the clearest examples of this transition. Although CCTA is primarily performed to evaluate cardiovascular disease, the scans often include lung regions as well. In many clinical settings, however, diagnostic attention has historically remained focused on cardiac findings, leaving pulmonary abnormalities such as lung nodules underutilized or overlooked.
Recent AI advances are changing that approach. New technologies can automatically identify lung nodules and pulmonary abnormalities from existing CT data without requiring additional imaging procedures. Medical researchers describe this as an expansion of “opportunistic analysis,” in which previously acquired medical images are reused to generate additional diagnostic insights.
Supporters of the technology argue that this model could improve both healthcare efficiency and public health accessibility by maximizing the value of already available medical data while reducing unnecessary follow-up scans.
The trend is also being reinforced by policy developments in the United States. The American College of Cardiology and the American Heart Association have expanded recommendations for cardiac CT utilization, contributing to growing demand for CCTA examinations. At the same time, the U.S. Centers for Medicare & Medicaid Services (CMS) recently introduced a new HCPCS reimbursement code, “G0680,” recognizing AI-assisted chest CT analysis as a distinct medical service.
Industry observers see the move as a sign that medical AI is increasingly becoming integrated into mainstream healthcare systems rather than remaining a supplementary research tool.
South Korean medical AI company Coreline Soft has emerged as one of the companies actively advancing this next generation of AI-driven imaging analysis. The company is currently expanding global clinical programs targeting the U.S. market while pursuing FDA 510(k) clearance for its AI-based lung nodule detection solution “AVIEW IPN” and quantitative pulmonary analysis platform “AVIEW Lung Metrics.”
Coreline Soft’s latest project was selected for Korea’s 2026 government-supported advanced medical device R&D initiative and will receive support over the next three years. While regulatory approval remains a major goal, industry analysts say the broader significance lies in validating AI-driven preventive healthcare models in real-world clinical environments.
The technological focus is also shifting from simple abnormality detection toward quantitative analysis and predictive monitoring. AI-powered pulmonary quantification technologies are increasingly designed to compensate for differences in imaging equipment, scan protocols, and noise conditions, enabling more standardized and reproducible results across hospitals and countries.
Such reproducibility is considered especially important in multinational clinical trials and global pharmaceutical research, where imaging data must be analyzed consistently despite variations in equipment and clinical environments.
Industry experts believe these technologies could eventually play a larger role in the growing digital biomarker market, where imaging-based AI tools are used to evaluate treatment responses and monitor disease progression during drug development and long-term care.
Demand for quantitative imaging analysis is also expected to rise alongside expanding markets for chronic lung disease therapies, including COPD and idiopathic pulmonary fibrosis (IPF). Analysts say medical AI is increasingly being viewed not merely as a diagnostic support tool, but as core infrastructure for preventive and chronic disease-focused healthcare systems.
Coreline Soft has been expanding collaborations with global medical institutions to validate the practical use of AI technologies within real hospital workflows. Industry observers note that the next stage of competition in medical AI will likely depend not only on algorithm accuracy, but also on real-world usability, interoperability, and data standardization.
As AI continues to reduce clinical workloads and improve early detection capabilities, healthcare systems themselves are gradually shifting from treatment-centered models toward prevention and long-term management.
